Akbari, H.; Taghizadeh-Hesary, F.; Bahadori, M. Mitochondria Determine Response to Anti-Programmed Cell Death Protein-1 (Anti-PD-1) Immunotherapy: An Evidence-Based Hypothesis. Mitochondrion, 2022, 62, 151–158. https://doi.org/10.1016/j.mito.2021.12.001.
Akbari, H.; Taghizadeh-Hesary, F.; Bahadori, M. Mitochondria Determine Response to Anti-Programmed Cell Death Protein-1 (Anti-PD-1) Immunotherapy: An Evidence-Based Hypothesis. Mitochondrion, 2022, 62, 151–158. https://doi.org/10.1016/j.mito.2021.12.001.
Akbari, H.; Taghizadeh-Hesary, F.; Bahadori, M. Mitochondria Determine Response to Anti-Programmed Cell Death Protein-1 (Anti-PD-1) Immunotherapy: An Evidence-Based Hypothesis. Mitochondrion, 2022, 62, 151–158. https://doi.org/10.1016/j.mito.2021.12.001.
Akbari, H.; Taghizadeh-Hesary, F.; Bahadori, M. Mitochondria Determine Response to Anti-Programmed Cell Death Protein-1 (Anti-PD-1) Immunotherapy: An Evidence-Based Hypothesis. Mitochondrion, 2022, 62, 151–158. https://doi.org/10.1016/j.mito.2021.12.001.
Abstract
It has been demonstrated that a decrease in cellular adenosine triphosphate (c-ATP) causes cellular dysfunction. T-cells are not an exception. One of their roles is to properly detect and eliminate cancer cells. These processes occur at the expense of ATP. Therefore, it can be concluded that a decrease in c-ATP can defect T-cell function and promote cancer evolution. In this article, we provide a hypothesis to describe the correlation between the expression of PD-1 protein on T-cells and their c-ATP levels. Moreover, we present the possible predictive factors of Anti–PD(L)-1 therapy which has not yet been determined definitely.
Keywords
T-lymphocytes; programmed cell death protein-1; mitochondria; adenosine triphosphate
Subject
Medicine and Pharmacology, Oncology and Oncogenics
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
